← REGULATORY CHANGES
FEDERAL REGISTER · NOTICESeptember 8, 2023NOTICE — NO LEGAL EFFECT

Endpoints and Trial Designs To Advance Drug Development in Kidney Transplantation; Public Meeting

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSNOTICE — NO LEGAL EFFECT
EFFECTIVE—
COMMENTS CLOSE—
APPLIES TO · SPEQ TAGDrug
Document type
Notice
Agency
Health and Human Services Department
Published
September 8, 2023
Document number
2023-19405
Docket
FDA-2023-N-3137
ABSTRACT

The Food and Drug Administration (FDA or we) is announcing the following public meeting on "Endpoints and Trial Designs To Advance Drug Development in Kidney Transplantation."

Abstract as published in the Federal Register.

READ THE FULL DOCUMENT

The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.

View on federalregister.gov →

That is what FDA published. A free account files it on your watchlist and sends one weekly email with whatever lands next.

Create a free account